Engineered immune cells take on lupus and other autoimmune diseases

NCT ID NCT05869955

Ongoing Disease control Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with standard treatments. The main goals are to check safety and find the right dose, while also looking for signs that the disease gets better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC-97540 (a type of CAR T cell therapy that targets CD19 on immune cells)
What this could lead to: If it works, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to other therapies.
What could go wrong: This is an early Phase 1 trial focused on safety, so it's too soon to know if it works. CAR T therapy can cause serious side effects like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic inflammatory myopathy myositis disease rheumatoid arthritis systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC INFLAMMATORY MYOPATHY RHEUMATOID ARTHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Local Institution - 0002

New York, New York, 10016, United States
Local Institution - 0003

Chapel Hill, North Carolina, 27599, United States
Local Institution - 0004

Seattle, Washington, 98104, United States
Local Institution - 0005

Cleveland, Ohio, 44195, United States
Local Institution - 0006

Jacksonville, Florida, 32224, United States
Local Institution - 0007

New York, New York, 10032, United States
Local Institution - 0008

Summit, New Jersey, 07901, United States
Local Institution - 0010

St Louis, Missouri, 63110, United States
Local Institution - 0011

New York, New York, 10029, United States
Local Institution - 0012

Rome, Lazio, 00168, Italy
Local Institution - 0013

Santander, Cantabria, 39008, Spain
Local Institution - 0014

Barcelona, Barcelona [Barcelona], 08035, Spain
Local Institution - 0015

Montpellier, Hérault, 34295, France
Local Institution - 0016

Lille, 59037, France
Local Institution - 0017

Erlangen, 91054, Germany
Local Institution - 0018

Paris, 75010, France
Local Institution - 0019

Leuven, Vlaams-Brabant, 3000, Belgium
Local Institution - 0020

Rennes, 35033, France
Local Institution - 0021

Barcelona, Catalunya [Cataluña], 08036, Spain
Local Institution - 0022

Rochester, Minnesota, 55905, United States
Local Institution - 0023

Rozzano, Milano, 20089, Italy
Local Institution - 0024

Denver, Colorado, 80218, United States
Local Institution - 0025

Berlin, 10117, Germany
Local Institution - 0028

Omaha, Nebraska, 68198, United States
Local Institution - 0029

Houston, Texas, 77030, United States
Local Institution - 0031

Ann Arbor, Michigan, 48109-2800, United States
Local Institution - 0033

Worcester, Massachusetts, 01655, United States
Local Institution - 0034

Houston, Texas, 77030, United States
Local Institution - 0035

Aurora, Colorado, 80045, United States
Local Institution - 0036

Dallas, Texas, 75390, United States
Local Institution - 0037

Detroit, Michigan, 48202, United States
Local Institution - 0038

Boston, Massachusetts, 02115, United States
Local Institution - 0039

Málaga, 29011, Spain
Local Institution - 0040

Nice, 06202, France
Local Institution - 0041

Leipzig, Saxony, 04103, Germany
Local Institution - 0042

Cologne, North Rhine-Westphalia, 50937, Germany
Local Institution - 0044

Pessac, Aquitaine, 33600, France
Local Institution - 0045

Magdeburg, Saxony-Anhalt, 39120, Germany
Local Institution - 0047

Düsseldorf, 40225, Germany
Local Institution - 0049

Würzburg, Bavaria, 97080, Germany
Local Institution - 0050

Córdoba, 14004, Spain
Local Institution - 0053

Chicago, Illinois, 60612, United States
Local Institution - 0056

Miami, Florida, 33136, United States
Local Institution - 0057

Seattle, Washington, 98105, United States
Local Institution - 0058

Seattle, Washington, 98109, United States
University of Massachusetts Chan Medical School

Worcester, Massachusetts, 01655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.